A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma

Ryo Yonezawa; Kazushi Shimamoto; Nobuyuki Kabasawa; Mizuki Sano; Shizuko Tanaka; Mitsuki Matsui; Hiroshi Harada; Tomiko Sunaga

doi:10.1016/j.lrr.2023.100365

A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma

Leuk Res Rep. 2023 Feb 25:19:100365. doi: 10.1016/j.lrr.2023.100365. eCollection 2023.

Authors

Ryo Yonezawa^{1

2}, Kazushi Shimamoto^{1

2}, Nobuyuki Kabasawa³, Mizuki Sano², Shizuko Tanaka^{1

2}, Mitsuki Matsui^{1

2}, Hiroshi Harada³, Tomiko Sunaga^{1

2}

Affiliations

¹ Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
² Department of Pharmacy, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama-shi, Kanagawa 227-8501, Japan.
³ Department of Medicine, Division of Hematology, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama-shi, Kanagawa, 227-8501, Japan.

Abstract

There are no reports of blood triglyceride (TG) levels increasing with the ABVD regimen. Herein, we present a case of Hodgkin's lymphoma that exhibited ABVD-induced blood TG increase. The patient was a 40-year-old Japanese man. Empiric therapy was initiated using the ABVD regimen for Hodgkin lymphoma. On day 58, the fasting blood TG concentration increased to 1,451 mg/dL. Since no adverse events were noted, 0.2 mg/day of pemafibrate was administered, and the ABVD regimen was continued. Blood TG levels should be periodically monitored during ABVD administration for the patients who are at high risk of increased blood TG levels.

Keywords: ABVD regimen; Adverse event; Blood triglycerides increased; Hodgkin lymphoma.

Publication types

Case Reports